• Breathtaking science

    Developing innovative therapeutics to transform

    the standard of care for respiratory diseases

  • Search for better science

    We aim to build a strong clinical R&D pipeline to

    target debilitating respiratory diseases

  • Our science

    Targeting respiratory diseases with significant unmet medical needs.

    There are millions of patients suffering globally from chronic, debilitating respiratory conditions that are not well treated by existing medicines. There is a real and pressing need for new treatments. We are focused on developing these treatments. Our efficient R&D outsourcing model gives us access to leading experts and organisations around the globe and our agility and focus on our core competencies provide the highest standards of pre-clinical and clinical development. 

    See our product pipeline

    Our strategy

    To progress projects with high commercial potential, whilst delivering both near-and long-term value to our shareholders.

    We have a clear view of the medical need and commercial potential of our novel products in global, multi-billion dollar markets. Making the right decisions now, with partners and investors, will help us identify the quickest and most effective route to market allowing us to potentially transform the lives of patients suffering from these debilating diseases, with the returns enabling us to continue this mission into the future. 

    Find out more about us

Verona Pharma

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD and cystic fibrosis. The Company is listed on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative theraputics.

Latest press releases

19 April 2017

Verona Pharma Announces Launch of Global Offering and Application to List on the NASDAQ Global Market
19 April 2017, London - Verona Pharma p…

18 April 2017

Verona Pharma Receives Authorization from the U.S. FDA to Proceed with Clinical Investigation of RPL554 with the Acceptance of Investigational New Drug Application
18 April 2017, London – Verona Pharma plc (AIM: VRP) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announced today that the U.S. Food and Drug Administration has authorized the initiation of a pharmacokinetic (“PK”) clinical trial in the U.S. for the Company’s product candidate, RPL554, with the acceptance of an Investigational New Drug appli…


Annual report 2016

Our latest annual report for the year ended 31 December 2016 is available in our downloads section

Current share price


-1.50 (-1.12%)

London Stock Exchange

Contact us

Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom

T: +44 (0)203 283 4200


Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom

Investor relations contact
E: info@veronapharma.com
T: +44 (0)203 283 4200

Nominated adviser and broker
N+1 Singer
One Bartholemew Lane
London EC2N 2AX

T: +44 (0)203 283 4200


Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us